Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL)
Author:
Yamazaki Azusa1, Ohkawa Ryunosuke2ORCID, Yamagata Yuka2, Horiuchi Yuna2, Lai Shao-Jui2, Kameda Takahiro2, Ichimura Naoya1, Tohda Shuji1, Tozuka Minoru3
Affiliation:
1. Clinical Laboratory , Medical Hospital, Tokyo Medical and Dental University (TMDU) , 1-5-45 Yushima , Bunkyo-ku , Tokyo 113-8510 , Japan 2. Analytical Laboratory Chemistry , Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU) , 1-5-45 Yushima , Bunkyo-ku , Tokyo 113-8510 , Japan 3. Life Science Research Center , Nagano Children’s Hospital , 3100 Toyoshina , Azumino 399-8288 , Japan
Abstract
Abstract
Triglyceride hydrolysis by lipoprotein lipase (LPL), regulated by apolipoproteins C-II (apoC-II) and C-III (apoC-III), is essential for maintaining normal lipid homeostasis. During triglyceride lipolysis, the apoCs are known to be transferred from very low-density lipoprotein (VLDL) to high-density lipoprotein (HDL), but the detailed mechanisms of this transfer remain unclear. In this study, we investigated the extent of the apoC transfers and their distribution in HDL subfractions, HDL2 and HDL3. Each HDL subfraction was incubated with VLDL or biotin-labeled VLDL, and apolipoproteins and lipids in the re-isolated HDL were quantified using western blotting and high-performance liquid chromatography (HPLC). In consequence, incubation with VLDL showed the increase of net amount of apoC-II and apoC-III in the HDL. HPLC analysis revealed that the biotin-labeled apolipoproteins, including apoCs and apolipoprotein E, were preferably transferred to the larger HDL3. No effect of cholesteryl ester transfer protein inhibitor on the apoC transfers was observed. Quantification of apoCs levels in HDL2 and HDL3 from healthy subjects (n = 8) showed large individual differences between apoC-II and apoC-III levels. These results suggest that both apoC-II and apoC-III transfer disproportionately from VLDL to HDL2 and the larger HDL3, and these transfers might be involved in individual triglyceride metabolism.
Funder
Japan Society for the Promotion of Science Hokuto Foundation for Bioscience
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference45 articles.
1. Aroner, S.A., Koch, M., Mukamal, K.J., Furtado, J.D., Stein, J.H., Tattersall, M.C., McClelland, R.L., and Jensen, M. K. (2018). High-density lipoprotein subspecies defined by apolipoprotein C-III and subclinical atherosclerosis measures: MESA (The multi-ethnic study of atherosclerosis). J. Am. Heart Assoc. 7, https://doi.org/10.1161/jaha.117.007824. 2. Baggio, G., Manzato, E., Gabelli, C., Fellin, R., Martini, S., Enzi, G.B., Verlato, F., Baiocchi, M.R., Sprecher, D.L., and Kashyap, M.L. (1986). Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J. Clin. Invest. 77: 520–527, https://doi.org/10.1172/jci112332. 3. Boyle, K.E., Phillips, M.C., and Lund-Katz, S. (1999). Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim. Biophys. Acta 1430: 302–312, https://doi.org/10.1016/s0167-4838(99)00009-6. 4. Breckenridge, W.C., Little, J.A., Steiner, G., Chow, A., and Poapst, M. (1978). Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N. Engl. J. Med. 298: 1265–1273, https://doi.org/10.1056/nejm197806082982301. 5. Bukberg, P.R., Le, N.A., Ginsberg, H.N., Gibson, J.C., Rubinstein, A., and Brown, W.V. (1985). Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J. Lipid Res. 26: 1047–1057.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|